Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup
The phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial showed no overall DFS improvement with adjuvant pembrolizumab plus chemotherapy, but a significant benefit in DFS for the dMMR subgroup (HR, 0.31; 95% CI, 0.14-0.69). The 2-year DFS rates were 92% and 80% in the pembrolizumab and placebo arms, respectively, for dMMR patients.
Reference News
Pembrolizumab Combo Shows DFS Benefit in dMMR Endometrial Cancer Subgroup
The phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial showed no overall DFS improvement with adjuvant pembrolizumab plus chemotherapy, but a significant benefit in DFS for the dMMR subgroup (HR, 0.31; 95% CI, 0.14-0.69). The 2-year DFS rates were 92% and 80% in the pembrolizumab and placebo arms, respectively, for dMMR patients.